ASCO 2017: Abiraterone Delays Metastatic Prostate Cancer Growth by 18 Months, Extends Survival

Chicago, IL (OncToday.com) Adding abiraterone acetate (Zytiga) plus prednisone to standard hormonal therapy for men newly diagnosed with high-risk, metastatic prostate cancer lowers the chance of death by 38%. In a phase III clinical trial of 1,200 men, abiraterone also more than doubled the median time until the cancer worsened, from 14.8 months to 33 months. 
Read more ...

ASCO 2017: Abiraterone Slows Advanced Prostate Cancer, Helps Patients Live Longer

Chicago, IL (OncToday.com) A clinical trial of nearly 2,000 men shows that adding abiraterone acetate (Zytiga) to a standard initial treatment regimen for high-risk, advanced prostate cancer lowers the relative risk of death by 37%. The 3-year survival rate was 76% with standard therapy alone, but 83% with standard therapy plus abiraterone. This is the largest study of abiraterone as first-line therapy for advanced prostate cancer. 
Read more ...

ASCO 2017: Perioperative Systemic Therapy for Kidney Cancer: Current Data and Ongoing Trials

Chicago, IL (OncToday.com) Dr. Uzzo gave the third and final talk in this excellent session highlighting systemic therapy in the management of kidney cancer. Focusing specifically on the role of perioperative systemic therapy (neoadjuvant [NAC] and adjuvant [AC]), he adeptly covered the prior literature and the future directions of this important intersection between surgery and systemic therapy. While his talk was extensive, below we will review the major highlights and key points.
Read more ...

ASCO 2017: Current Therapeutics of Kidney Cancer: Landmark Trials

Chicago, IL (OncToday.com) Dr. Vaishampayan provided an excellent walk down memory lane, highlighting the landmark trials in kidney cancer over the last 20 years at this morning’s ASCO 2017 annual meeting session “Evolving Treatment Paradigm in Renal Cell Carcinoma.”
Read more ...

ASCO 2017: Stereotactic Body Radiation: What Is Its Role in Advanced Disease?

Chicago, IL (OncToday.com) Dr. Tran started off the “How to Integrate Multimodal Therapy Into the Management of Castration-Resistant Prostate Cancer” session at the ASCO 2017 annual meeting with his talk on the role of stereotactic body radiation in advanced disease. 
Read more ...

ASCO 2017: Targeting DNA Repair Mutations in Metastatic Castration-Resistant Prostate Cancer

Chicago, IL (OncToday.com) Dr. Johann De Bono from London, UK presented the final talk of the “How to Integrate Multimodal Therapy Into the Management of Castration-Resistant Prostate Cancer (CRPC)” at the 2017 ASCO annual meeting session. His presentation was assessing DNA repair mutations among men with CRPC.
Read more ...

ASCO 2017: Chemotherapy for Metastatic Castration-Resistant Prostate Cancer: Which Patient? Which Time?

Chicago, IL (OncToday.com) At 2017 ASCO annual meeting session on “How to Integrate Multimodal Therapy Into the Management of Castration-Resistant Prostate Cancer CRPC”, Dr. Aparicio discussed the role of chemotherapy, specifically aspects regarding which patient to treat and when to treat. 
Read more ...
Page 1 of 4
@OncToday